Aberrant expression of the Rb pathway proteins in soft tissue sarcomas

Applied Immunohistochemistry and Molecular Morphology

Volumn 14, Issue 4, 2006, Pages 397-403

  Sabah, Muna ^a   Cummins, Robert ^a   Leader, Mary ^a   Kay, Elaine ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

Cell cycle; High grade; Intermediate grade; Low grade; Rb pathway; Soft tissue sarcoma

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROTEIN P16; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1;

ARTICLE; CANCER GRADING; CARCINOGENESIS; CELL CYCLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOFT TISSUE SARCOMA;

CELL CYCLE PROTEINS; HUMANS; LIPOSARCOMA; PROGNOSIS; RETINOBLASTOMA PROTEIN; SARCOMA; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33751363185     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000190176.06200.68     Document Type: Article

References (43)

1. Reed SI. Control of the G1/S transition. Cancer Surv. 1997;29:7-23.
2. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323-330.
3. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501-1512.
4. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
5. Fletcher CD, Unni KK, Mertens F. Pathology and Genetics of Tumours of Soft Tissue and Bone. Oxford: Oxford University Press; 2002.
6. Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15:350-362.
7. Weiss SW, Goldblum JR. Enzinger and Weiss's Soft Tissue Tumors. Chicago: Mosby; 2001.
8. Antonescu CR, Leung DH, Dudas M, et al. Alterations of cell cycle regulators in localized synovial sarcoma: a multifactorial study with prognostic implications. Am J Pathol. 2000;156:977-983.
9. Yoo J, Park SY, Kang SJ, et al. Altered expression of G1 regulatory proteins in human soft tissue sarcomas. Arch Pathol Lab Med. 2002;126:567-573.
10. Karpeh MS, Brennan MF, Cance WG, et al. Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas. Br J Cancer. 1995;72:986-991.
11. Cordon-Cardo C. Molecular biology of sarcomas. In: DeVita VT, Hellman S, Rosenberg SA, eds. Principles and Practice of Oncology. Philadelphia: JB Lippincott; 1997:1731-1738.
12. Clurman BE, Roberts JM. Cell cycle and cancer. J Natl Cancer Inst. 1995;87:1499-1501.
13. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer. 1986;53:661-671.
14. DerKinderen DJ, Koten JW, Nagelkerke NJ, et al. Non-ocular cancer in patients with hereditary retinoblastoma and their relatives. Int J Cancer. 1988;41:499-504.
15. Stratton MR, Williams S, Fisher C, et al. Structural alterations of the RB1 gene in human soft tissue tumours. Br J Cancer. 1989;60:202-205.
16. Reissmann PT, Simon MA, Lee WH, et al. Studies of the retinoblastoma gene in human sarcomas. Oncogene. 1989;4:839-843.
17. Cance WG, Brennan MF, Dudas ME, et al. Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med. 1990;323:1457-1462.
18. Cohen JA, Geradts J. Loss of RB and MTS1/CDKN2 (p16) expression in human sarcomas. Hum Pathol. 1997;28:893-898.
19. Wang J, Coltrera MD, Gown AM. Abnormalities of p53 and p110RB tumor suppressor gene expression in human soft tissue tumors: correlations with cell proliferation and tumor grade. Mod Pathol. 1995;8:837-842.
20. Dei Tos AP, Piccinin S, Doglioni C, et al. Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma. Am J Pathol. 1997;151:1531-1539.
21. Dei Tos AP, Maestro R, Doglioni C, et al. Tumor suppressor genes and related molecules in leiomyosarcoma. Am J Pathol. 1996;148:1037-1045.
22. Kratzke RA, Greatens TM, Rubins JB, et al. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res. 1996;56:3415-3420.
23. Geradts J, Kratzke RA, Crush-Stanton S, et al. Wild-type and mutant retinoblastoma protein in paraffin sections. Mod Pathol. 1996;9:339-347.
24. Creager AJ, Cohen JA, Geradts J. Aberrant expression of cell-cycle regulatory proteins in human mesenchymal neoplasia. Cancer Detect Prev. 2001;25:123-131.
25. Muller H, Lukas J, Schneider A, et al. Cyclin D1 expression is regulated by the retinoblastoma protein. Proc Natl Acad Sci USA. 1994;91:2945-2949.
26. Kim SH, Lewis JJ, Brennan MF, et al. Overexpression of cyclin D1 is associated with poor prognosis in extremity soft-tissue sarcomas. Clin Cancer Res. 1998;4:2377-2382.
27. Khatib ZA, Matsushime H, Valentine M, et al. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res. 1993;53:5535-5541.
28. Yao J, Pollock RE, Lang A, et al. Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma. Clin Cancer Res. 1998;4:1065-1070.
29. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704-707.
30. Serrano M, Lee H, Chin L, et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996;85:27-37.
31. Orlow I, Drobnjak M, Zhang ZF, et al. Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: effect on survival. J Natl Cancer Inst. 1999;91:73-79.
32. Maelandsmo GM, Berner JM, Florenes VA, et al. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas-relationship to amplification and mRNA levels of CDK4 and CCND1. Br J Cancer. 1995;72:393-398.
33. Schneider-Stock R, Walter H, Haeckel C, et al. Gene alterations at the CDKN2A (p16/MTS1) locus in soft tissue tumors. Int J Oncol. 1998;13:325-329.
34. Birindelli S, Perrone F, Oggionni M, et al. Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest. 2001;81:833-844.
35. Geradts J, Kratzke RA, Niehans GA, et al. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res. 1995;55:6006-6011.
36. Benassi MS, Molendini L, Gamberi G, et al. Alteration of pRb/p16/ cdk4 regulation in human osteosarcoma. Int J Cancer. 1999;84:489-493.
37. Hengst L, Reed SI. Translational control of p27Kip1 accumulation during the cell cycle. Science. 1996;271:1861-1864.
38. Sgambato A, Cittadini A, Faraglia B, et al. Multiple functions of p27(Kip1) and its alterations in tumor cells: a review. J Cell Physiol. 2000;183:18-27.
39. Kawauchi S, Goto Y, Liu XP, et al. Low expression of p27(Kip1), a cyclin-dependent kinase inhibitor, is a marker of poor prognosis in synovial sarcoma. Cancer. 2001;91:1005-1012.
40. Kourea HP, Cordon-Cardo C, Dudas M, et al. Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas. Am J Pathol. 1999;155:1885-1891.
41. Oliveira AM, Nascimento AG, Okuno SH, et al. p27(kip1) protein expression correlates with survival in myxoid and round-cell liposarcoma. J Clin Oncol. 2000;18:2888-2893.
42. Fernandez-Figueras MT, Puig L, Penin RM, et al. Decreased immunoreactivity for cell-cycle regulator p27(Kip1) in Kaposi's sarcoma correlates with higher stage and extracutaneous involvement. J Pathol. 2000;191:387-393.
43. Kawamata N, Morosetti R, Miller CW, et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res. 1995;55:2266-2269.